EnGen Bio

A Vaccine and Therapy to Provide Lifetime Protection from Flu Pandemics

https://wefunder.com/engen.bio.llc

Total raised on Wefunder: 1188482

Total investors: 867

Quick facts

  • Potential for universal prevention of Type A flu and all flu pandemics in humans and animals.
  • Our vaccine could save 50K-250K lives a year and prevent untold suffering of millions caused by flu.
  • Veterinary applications to prevent all dog, horse, pig and bird flus.
  • Peak sales could reach 2.6B in the U.S. alone, in an $11.4B global market (not guaranteed).
  • 8 issued flu vaccine patents in major strategic markets.
  • Potential for early liquidity.
  • Experienced team of entrepreneurs with a combined total of 6 FDA approved drugs and >50 patents.
  • >50% of our lead investors are biotech execs and MDs who've vetted the science & its potential.

Team profiles

Featured investor profiles

EnGen Bio

A Vaccine and Therapy to Provide Lifetime Protection from Flu Pandemics

Never miss an update

  • Join the EnGen Bio community. Follow their journey as they grow.
  • Stay in the loop if they ever decide to raise a round.
Pitch Video
Investor Panel

Investor Panel

Shu interviewed EnGen Bio on April 7, 2021. Play Video
Shu Li
Shu Li
CEO and co-founder of Petri-Bio
Strengths
says, "EnGen Bio has super experienced founder and very compelling technology. Their go-to-market strategy might sound a little different than most consumer product companies, but it's in fact very capital efficient and strategic approach for a biotech startup."
Advice
says, "One of the urgent questions I'm sure a lot of us are wondering is: when can we get this lifelong protective flu shot? I'd like to see more information about the potential partnership and expected timeline."

What Investors Say

Director at Barnes & Noble
LEAD INVESTOR
Invested $50,000 this round
Dr. Mark Alfenito and his team combine that exceedingly rare combination of brilliant scientists with savvy businessmen to create a biotech company focused on ending the influenza scourge while keeping significant value and future potential earnings in the company.  They are passionate about the science and their investors.  During this pandemic, there is heightened awareness on this sector.  The company is poised to make great discoveries that will be beneficial to science and medicine while extremely lucrative to investors. I am especially attracted to the 1X liquidation preference, meaning that upon a liquidity event of sufficient magnitude, we all get paid back on our initial investment before any distributions are made.  Everything beyond that point is icing on the cake.  This is relatively unique, and demonstrates how much EnGen Bio’s board and officers are looking out for the best interests of the investors.
What People Say